Early prostate cancer antigen-2
Early prostate cancer antigen-2 (EPca-2)
Early prostate cancer antigen-2 (EPca-2), pronounced as /ɪərli prɒsteɪt kænsər æntɪdʒən tuː/, is a biomarker identified in the early stages of prostate cancer. The etymology of the term is derived from its role in the early detection of prostate cancer.
Definition
EPca-2 is a protein that is overexpressed in prostate cancer cells. It is used as a biomarker to detect the presence of prostate cancer at an early stage. The detection of EPca-2 can be done through a blood test or a biopsy.
History
The discovery of EPca-2 was made in the late 20th century as part of the ongoing research into early detection methods for prostate cancer. The identification of this biomarker has significantly improved the early detection and treatment of prostate cancer.
Clinical Significance
The presence of EPca-2 in the blood or tissue samples can indicate the presence of prostate cancer. It is particularly useful in detecting prostate cancer at an early stage when the disease is most treatable. The detection of EPca-2 is often used in conjunction with other tests such as the Prostate-Specific Antigen (PSA) test.
Related Terms
External links
- Medical encyclopedia article on Early prostate cancer antigen-2
- Wikipedia's article - Early prostate cancer antigen-2
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski